Skip to main content
. 2021 Mar 25;10(3):29. doi: 10.1167/tvst.10.3.29

Figure 5.

Figure 5.

Total fluid burden—combined intraretinal and subretinal fluid during matched phase. (A) Proportion of participants with true zero fluid in treatment agnostic (gray), brolucizumab (blue), and aflibercept (red) groups. (B) Proportion of participants with minimal fluid or less in treatment agnostic (gray), brolucizumab (blue), and aflibercept (red) groups. *P < 0.05 brolucizumab versus aflibercept.